• Home
  • Search Results
  • G9a Promotes Breast Cancer Recurrence through Repression of a Pro-inflammatory Program.

G9a Promotes Breast Cancer Recurrence through Repression of a Pro-inflammatory Program.

Cell reports (2020-11-05)
Nathaniel W Mabe, Nina Marie G Garcia, Shayna E Wolery, Rachel Newcomb, Ryan C Meingasner, Brittany A Vilona, Ryan Lupo, Chao-Chieh Lin, Jen-Tsan Chi, James V Alvarez

Dysregulated gene expression is a common feature of cancer and may underlie some aspects of tumor progression, including tumor relapse. Here, we show that recurrent mammary tumors exhibit global changes in gene expression and histone modifications and acquire dependence on the G9a histone methyltransferase. Genetic ablation of G9a delays tumor recurrence, and pharmacologic inhibition of G9a slows the growth of recurrent tumors. Mechanistically, G9a activity is required to silence pro-inflammatory cytokines, including tumor necrosis factor (TNF), through H3K9 methylation at gene promoters. G9a inhibition induces re-expression of these cytokines, leading to p53 activation and necroptosis. Recurrent tumors upregulate receptor interacting protein kinase-3 (RIPK3) expression and are dependent upon RIPK3 activity. High RIPK3 expression renders recurrent tumors sensitive to necroptosis following G9a inhibition. These findings demonstrate that G9a-mediated silencing of pro-necroptotic proteins is a critical step in tumor recurrence and suggest that G9a is a targetable dependency in recurrent breast cancer.

Product Number
Product Description

C646, ≥98% (HPLC)
RG108, ≥98% (HPLC), powder
N-Oxalylglycine, ≥98% (HPLC)
BIX, ≥98% (HPLC)
SGC0946, ≥98% (HPLC)
AGK2, ≥97% (HPLC), powder
PFI-1, ≥98% (HPLC)
GSK2801, ≥98% (HPLC)
UNC1215, ≥98% (HPLC)

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.